Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04045496 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Jacobio Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04045496 is a Phase 1 study that has completed, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 40 participants.
The verdict
NCT04045496, a Phase 1 study, has completed, sponsored by Jacobio Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Interventions
- DRUG JAB-3312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04045496
The ClinicalTrials.gov registry entry for NCT04045496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jacobio Pharmaceuticals Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JAB-3312 is the first listed.
NCT04045496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04045496 about?
NCT04045496 is a clinical study titled "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors". This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-33...
What is the current status of trial NCT04045496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-09-26. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT04045496?
The interventions under investigation include: JAB-3312 (DRUG).
Who is sponsoring clinical trial NCT04045496?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.